In vitro activity of BAY v 3522, a new cephalosporin for oral administration.
AUTOR(ES)
Hodges, T L
RESUMO
The activity of BAY v 3522 was tested against over 500 clinical bacterial isolates and compared with the activities of ampicillin, amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, and/or ciprofloxacin, erythromycin, and metronidazole. BAY v 3522 activity against staphylococci and streptococci equaled or exceeded those of the other agents. BAY v 3522 exhibited no significant advantage over cefaclor, cefuroxime, or cephalexin against gram-negative bacilli.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171947Documentos Relacionados
- In Vitro Activity of BAY v 3522, a New Cephalosporin for Oral Administration
- In vitro activity of BAY v 3522, a new oral cephalosporin.
- In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents.
- Mechanism of action of BAY v 3522, a new cephalosporin with unusually good activity against enterococci.
- In vitro activity of BMY-28100, a new oral cephalosporin.
